A5103130275- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- COVID-19 Impact on Reproduction
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- COVID-19 and Mental Health
- Bacterial Infections and Vaccines
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Peptidase Inhibition and Analysis
- COVID-19 and healthcare impacts
- Vascular Malformations and Hemangiomas
- Poisoning and overdose treatments
- Orthopedic Infections and Treatments
- Lung Cancer Diagnosis and Treatment
- Circular RNAs in diseases
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Gestational Trophoblastic Disease Studies
- Neurological and metabolic disorders
- COVID-19 Clinical Research Studies
- Breast Lesions and Carcinomas
- Traumatic Brain Injury and Neurovascular Disturbances
Hospital Universitario 12 De Octubre
2020-2025
Universidad Europea
2023
Research Institute Hospital 12 de Octubre
2023
Universidad Autónoma de Madrid
2023
Hospital La Paz Institute for Health Research
2023
Hospital Universitario de Fuenlabrada
2012-2022
Hospital Universitario Virgen del Rocío
2020
The prognosis of patients with advanced high-grade (G3) digestive neuroendocrine neoplasms (NENs) is rather poor. addition immune checkpoint inhibition to platinum-based chemotherapy may improve survival. NICE-NEC (NCT03980925) a single-arm, phase II trial that recruited chemotherapy-naive, unresectable or metastatic G3 NENs gastroenteropancreatic (GEP) unknown origin. Patients received nivolumab 360 mg intravenously (iv) on day 1, carboplatin AUC 5 iv and etoposide 100 mg/m
Abstract Patients with advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) have impaired nutritional and physical performance due to the cancer pathophysiology its treatment. The NUTRIGETNE study sought characterize status of patients GEP-NENs in Spain. This is a cross-sectional that included receiving active oncological had complete examination, anthropometry, bioelectrical impedance, dynamometry, laboratory analysis, comprehensive risk assessment. Malnutrition was defined...
BACKGROUNDIn metastatic colorectal cancer (mCRC), the anti-vascular endothelial growth factor drug bevacizumab (BVZ) plus chemotherapy significantly improves progression-free survival compared to (CT) alone.This benefit is not, however, observed in all patients.While increased chemokine CXCL5 gene expression promoting angiogenesis has been proposed as a prognostic mCRC biomarker, few studies have examined its relationship with efficacy.This study sought analyze tumor six patients different...
The addition to chemotherapy of anti-HER2 drugs such as trastuzumab or pertuzumab has improved outcomes in HER2-positive breast cancer patients. However, resistance these some patients remains a major concern. This study examines the possible association between response neoadjuvant treatment and presence 28 SNPs 17 genes involved different cell processes (PON1, CAT, GSTP1, FCGR3, ATM, PIK3CA, HER3, BARD1, LDB2, BRINP1, chr6 intergenic region, RAB22A, TRPC6, LINC01060, EGFR, ABCB1, HER2)....
Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor A. It currently used in combination with chemotherapy treat metastatic colorectal cancer. This therapy not equally effective every patient; some, mechanisms of resistance arise remain poorly understood. The aim the present work was determine whether expression 26 miRNAs could be associated effectiveness bevacizumab plus chemotherapy, progression-free survival (PFS), and overall (OS) cancer.Paraffin-embedded...
TPS3177 Background: Everolimus is the only approved drug for treatment of patients with neuroendocrine tumors (NETs) lung and thymic origin, showing a median progression-free survival (PFS) 11 months. Retrospective data peptide receptor radionuclide therapy (PRRT) have demonstrated promising activity in somatostatin (SSTR)-positive NETs. This study aims to compare efficacy, safety, patient-reported outcomes 177 Lu-edotreotide versus standard care everolimus advanced Methods: The LEVEL trial...
TPS4210 Background: VCN-01 is a modified oncolytic adenovirus type 5 (Ad5) designed to replicate selectively in cancer cells with dysfunctional RB1-E2F pathway and express hyaluronidase enhance virus intratumoral spread facilitate chemotherapy immune extravasation into the tumor. Results obtained previous phase I trial patients solid tumors, including metastatic pancreatic cancer, showed that single systemic administration of feasible has an acceptable safety profile alone or when combined...
Angiogenesis pathway genes show substantial genetic variability causing inter-individual differences in responses to anti-angiogenic drugs. We examined 20 single nucleotide polymorphisms (SNPs) 13 of these predict tumour response and clinical outcome measured as progression free survival (PFS) overall (OS) 57 patients with metastatic colorectal cancer (mCRC) given bevacizumab plus chemotherapy. SNPs were detected (iPLEX® Assay) genomic DNA extracted from formalin-fixed paraffin-embedded...
HER2-positive breast cancer (BC) is an aggressive subtype that affects 20-25% of BC patients. For these patients, neoadjuvant therapy a good option targets pathological complete response (pCR) and more breast-conserving surgery. In effect, the outcomes patients with have dramatically improved since introduction anti-HER2 antibodies such as trastuzumab (TZ) and/or pertuzumab (PZ) added to chemotherapy. This study sought examine whether correlation exists between copy number variations (CNVs)...
Abstract Purpose Clinical practice guidelines recommend that all patients with metastatic colorectal cancer (mCRC) should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). We aimed to describe the dMMR/MSI-H testing in mCRC Spanish centers. Methods Multicenter, observational retrospective study included newly diagnosed who progressed a stage from early/localized stages. Results Three hundred were May 2020 through 2021, median age of 68 years, and two...
Sindrome de encefalopatia posterior reversible asociado a quimioterapia. Gemcitabina como agente causal.
Lurbinectedin received FDA approval for the treatment of small cell lung cancer and has shown activity in neuroendocrine tumours from other primary sites (Eur J Cancer 2022; 172: 340-348). Previous data synergy between lurbinectedin irinotecan (Cancer Res2013;73 (8 Supl 1) Abs 5499). We show here results a phase I/II study expansion cohort evaluating 2.0 mg/m2 plus 75 with G-CSF prophylaxis pre-treated G3 GEP-NECs. Phase II stage included 20 pts (Ki67>20%) poorly differentiated NECs GEP or...
Pediatría Basada en la Evidencia En
Colorectal cancer is one of the most prevalent cancers nowadays. In metastatic setting, diagnosis and treatment have relied on tumor tissue analysis. However, different limitations this approach recently opened door to introduction liquid biopsy in clinical setting. Liquid provides real-time information about its heterogeneity a simple, non-invasive, repeatable way. There are several analytes that can be sought: exosomes, circulating cells, DNA, showing promising results areas early...
Introduction: Pancreatic tumours are a systemic disease with early metastatic spread and poor survival rates. In the past years we have experienced transition where FOLFIRINOX Gemcitabine plus NAB-paclitaxel settled as first line therapy. There is some controversy about second line, no standard regimen. The challenge of using more than one treatment based on patients' clinical conditions since they not always fit to withstand treatment. Most studies described stratify patients according...